The King's condition is "benign" and he will be treated in the hospital next week for a "corrective procedure", Buckingham Palace said a statement released
on Wednesday.
"In common with thousands of men each year, the King has sought treatment for an enlarged prostate," the Palace said.
Because of the upcoming surgery, Charles had to postpone all meetings and events planned for this week.
The Palace informed that the King's public engagements will be "postponed for a short period of recuperation."
Charles, 75, wanted to share the details of his diagnosis to encourage more men who may be experiencing symptoms to get their conditions checked.
With scarlet fever currently circulating in England, the UK Health Security Agency (UKSHA) has urged parents to remain vigilant for potential symptoms in
children.
Also known as scarlatina, it is an infectious disease triggered by group A strep bacteria that can lead to symptoms such as fever, a sandpapery rash, sore throat
and swollen tonsils.
The latest data published by the UKHSA showed that a total of 19,528 cases of scarlet fever were reported in the 2023/24 season, of which 12,176 cases occurring
between 1 January and 24 March 2024.
While the number of cases recorded this year is lower than those recorded during the same period in 2023, which totaled 15,933 cases, it exceeds the average for
the previous five years.
"Scarlet fever is a common childhood illness, although it can affect anyone of any age," said Dr Theresa Lamagni at UKHSA.
Parents are advised to contact their GP practice or NHS111 when their GP is unavailable, if they suspect they or their child are experiencing symptoms of scarlet
fever.
Amid the rapid rise in semaglutide usage, a study has suggested a potential risk of a rare eye condition associated with the weight loss drug.
Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is available under the brand name Ozempic (by Novo Nordisk) in a lower-dose form for managing
type 2 diabetes mellitus (T2DM), and as Wegovy (also by Novo Nordisk) in a higher-dose form for weight management in patients with high body mass indexes.
Anecdotal evidence has indicated that semaglutide might be linked to nonarteritic anterior ischemic optic neuropathy (NAION).
To investigate this potential connection, researchers in the United States analysed data over a six-year period from nearly 17,000 neuro-ophthalmology patients at
Massachusetts Eye and Ear Hospital in Boston, Massachusetts, all of whom had no prior history of NAION.